Elsevier

The Lancet

Volume 379, Issue 9812, 21–27 January 2012, Page 204
The Lancet

Comment
Offline: The scandal of device regulation in the UK

https://doi.org/10.1016/S0140-6736(12)60070-1Get rights and content

References (0)

Cited by (17)

  • Barriers and facilitators of patient access to medical devices in Europe: A systematic literature review

    2019, Health Policy
    Citation Excerpt :

    The unavailability of information in included publications regarding the steps shown in Fig. 1 was not specifically mentioned for each country. Market access to MDs was the main objective in nineteen publications, and concerned five countries: France (n = 3) [16,50,51], Germany (n = 4) [27,43,47,49], the UK (n = 11) [6,8,10,22–24,26,43,52–54], Sweden (n = 2) [48,53], and/or Poland (n = 1) [25]. Uniform market approval procedures were described for these EU member states.

  • From biomarkers to medical tests: The changing landscape of test evaluation

    2014, Clinica Chimica Acta
    Citation Excerpt :

    Healthcare funders and regulators are indicating that such marginal improvements are less likely to be funded or reimbursed in the future. Professional, public and government organizations have criticized the current FDA approval and CE marking processes for failing to provide patients with safer, higher quality and more effective devices [3,32,43]. While it is clear that a more integrated regulatory framework is needed, it must be one that does not stifle innovation in the medical and in vitro diagnostic medical device industry.

  • Chemical and physicochemical properties of the high cohesive silicone gel from Poly Implant Prothèse (PIP) breast prostheses after explantation: A preliminary, comparative analytical investigation

    2013, Journal of Pharmaceutical and Biomedical Analysis
    Citation Excerpt :

    Also in this case, only D4, D5 and D6 (% match 74–91%) were unambiguously identified, while astonishingly different structural attributions of the peaks at higher retention times were done. According to this report, these species were barely undetectable (or present in very low amounts) in implants from other commercial brands (n = 6) of undisclosed origin [34]. If some discrepancies between our results and those above reported may be reasonably explained (for instance, the different structural assignments from MHRA may arise from a low experimental spectra/spectral library match, reported in the probability range 9–50%), on the other hand they highlighted a number of critical points that we believe of fundamental importance.

View all citing articles on Scopus
View full text